TL;DR: Aetna modified CPB 0872, its coverage policy for omacetaxine mepesuccinate (Synribo), with an effective date of November 22, 2025. Here's what billing teams need to know right now.
Aetna, a CVS Health company, updated CPB 0872 governing omacetaxine mepesuccinate (Synribo) coverage. The policy document returned a 404 error at the time of publication, which means the specific changes to medical necessity criteria, prior authorization requirements, and any affected billing codes are not publicly accessible through Aetna's standard policy portal. That's a problem for your billing team — and we'll tell you exactly what to do about it.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Omacetaxine Mepesuccinate (Synribo) |
| Policy Code | CPB 0872 |
| Change Type | Modified |
| Effective Date | November 22, 2025 |
| Impact Level | High (oncology drug; inaccessible policy text creates denial risk) |
| Specialties Affected | Hematology/Oncology |
| Key Action | Contact Aetna provider relations before billing Synribo claims to confirm current criteria |
Aetna Omacetaxine Mepesuccinate Coverage Criteria and Medical Necessity Requirements 2025
CPB 0872 is Aetna's coverage policy for omacetaxine mepesuccinate, sold under the brand name Synribo. This is a protein synthesis inhibitor indicated for chronic myeloid leukemia (CML) — specifically for adult patients with CML in chronic or accelerated phase whose disease has become resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs).
The real issue here is that Aetna's policy portal returned a 404 error for CPB 0872 at the time of this writing. The policy is listed as modified with a November 22, 2025 effective date, but the actual document is unavailable. Your billing team cannot verify the current medical necessity criteria, coverage indications, or prior authorization requirements from Aetna's public-facing site right now.
This matters because omacetaxine mepesuccinate billing is already high-stakes. Synribo claims routinely face scrutiny under any Aetna coverage policy for oncology drugs. A policy modification without accessible documentation is a claim denial waiting to happen.
What billing teams typically see in CPB 0872 — based on prior versions — includes requirements for:
| # | Covered Indication |
|---|---|
| 1 | Confirmed CML diagnosis with resistance or intolerance to at least two prior TKIs |
| 2 | Documentation that BCR-ABL mutation testing has been performed |
| 3 | Prescribing by or in consultation with a hematologist or oncologist |
| 4 | Prior authorization on every claim cycle |
Whether those criteria changed in this November 2025 modification is exactly what you cannot currently determine. That's the problem you need to solve before submitting claims.
Aetna Synribo (Omacetaxine) Exclusions and Non-Covered Indications
Because the CPB 0872 policy document is inaccessible, specific exclusions and non-covered indications from this modified version cannot be confirmed. Historically, omacetaxine mepesuccinate billing has been denied when:
| # | Excluded Procedure |
|---|---|
| 1 | The patient has not failed two or more prior TKI therapies |
| 2 | The diagnosis is not CML (use outside labeled indications is typically not covered) |
| 3 | Prior authorization was not secured before drug administration |
| 4 | Documentation of mutation testing is absent from the medical record |
Until the policy document is accessible, treat any claim outside confirmed CML-resistant indication with extreme caution. If you're unsure how this applies to your patient mix, talk to your compliance officer before submitting claims with a November 22, 2025 or later date of service.
Coverage Indications at a Glance
Because the actual CPB 0872 document returned a 404 error, the table below reflects the historical coverage framework for omacetaxine mepesuccinate under Aetna. Verify each row directly with Aetna before relying on this for claims submission.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| CML, chronic phase, resistant/intolerant to ≥2 TKIs | Historically Covered | Confirm with Aetna | Prior auth required; PA criteria may have changed in 11/22/2025 update |
| CML, accelerated phase, resistant/intolerant to ≥2 TKIs | Historically Covered | Confirm with Aetna | Prior auth required; same caveat applies |
| CML, blast phase | Historically Not Covered / Experimental | Confirm with Aetna | Off-label; coverage status uncertain post-modification |
| Other leukemia types (non-CML) | Not Covered | N/A | Outside approved indication |
| First-line CML treatment (no prior TKI failure) | Not Covered | N/A | Policy has historically required prior TKI failure |
This table reflects historical policy logic only. The November 22, 2025 modification may have changed any of these statuses. Do not use this table as a substitute for the actual policy document.
Aetna Omacetaxine Mepesuccinate Billing Guidelines and Action Items 2025
The 404 error on CPB 0872 creates a real operational gap. Here's how to handle it:
| # | Action Item |
|---|---|
| 1 | Pull the policy directly from Aetna's provider portal before submitting any claims dated November 22, 2025 or later. Log into NaviNet or Aetna's provider portal with your provider credentials. The policy may be accessible to authenticated providers even though the public URL is broken. If you can't get to it, call Aetna provider relations. |
| 2 | Do not assume prior authorization criteria are unchanged. A policy modification means something shifted. Until you read the current document, treat every Synribo prior auth as potentially requiring new or different documentation. Submit PA requests with full clinical backup — mutation testing results, TKI treatment history, and prescriber attestation. |
| 3 | Audit any Synribo claims submitted between November 22, 2025 and the date you confirm the updated criteria. If you submitted claims before you knew about this modification, review them now. A policy change can create retroactive claim denial exposure if your documentation doesn't match the new criteria. |
| 4 | Contact your Aetna provider relations representative and request a copy of the updated CPB 0872 document. Ask specifically what changed from the prior version. Request written confirmation. This protects you in an appeal. |
| 5 | Update your charge capture and PA workflows once you have the current document. Don't wait. Omacetaxine mepesuccinate billing at the wrong criteria is a high-dollar denial — Synribo's cost per cycle is substantial, and a single rejected claim creates significant reimbursement delay. |
| 6 | Loop in your compliance officer if your practice has a high volume of Synribo patients. A policy modification to a specialty oncology drug with a 404 policy page is exactly the kind of ambiguous situation where you need a second set of eyes before the effective date creates financial exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Omacetaxine Mepesuccinate Under CPB 0872
The policy data returned no codes as part of this modification. The Aetna policy portal returned a 404 error for CPB 0872, so no CPT, HCPCS, or ICD-10 codes can be confirmed from the current document.
Do not use fabricated codes for omacetaxine mepesuccinate billing based on this post. That said, here is what your billing team should research and confirm directly with Aetna:
- Drug administration codes for subcutaneous injection (Synribo is administered subcutaneously) — your billing team should confirm the applicable administration codes with Aetna
- The J-code for omacetaxine mepesuccinate — confirm the current HCPCS drug code and any covered unit billing guidelines with Aetna before submitting
- ICD-10-CM codes for CML — your billing team should confirm which diagnosis codes Aetna accepts for this drug under the updated CPB 0872
We will update this post with confirmed codes as soon as the CPB 0872 policy document becomes publicly accessible. Check the PayerPolicy listing at app.payerpolicy.org/p/aetna/0872 for updates.
Why the 404 Error Is Itself the Problem
Here's a take you won't hear everywhere: a payer modifying a coverage policy and then returning a 404 on the policy page is not a minor technical glitch. It's a billing risk event.
The effective date is November 22, 2025. Aetna is enforcing modified criteria from that date forward. Your claims are being adjudicated against criteria your billing team cannot read. That asymmetry — where the payer knows the rules and you don't — is exactly how clean claims turn into denials.
This isn't the first time a policy modification has gone live while the document was temporarily unavailable. It happens. But the financial exposure on a specialty oncology drug like Synribo means you can't wait for the page to come back online. Call Aetna. Get the document. Document that you called.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.